Top 10 Pharma Drug Discovery Delivery Capital Raises and Investors in the U.S. – June 1st – 30th, 2026
Several interesting transactions closed in the Pharma Drug Discovery Delivery sector over the past month. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.
PIPE
- Aurinia Pharmaceuticals, delivers therapies to people living with autoimmune diseases with high unmet medical needs, received CAD 3.15 million of development capital from Tang Capital Management through a private placement.
Buyout/LBO
- Celerion, early-phase clinical research and bioanalytical testing services for pharmaceutical and biotechnology companies, was acquired by Thomas H. Lee Partners through a $1.8 billion LBO.
- Clinical Neuroscience Solutions, clinical research and trial management services for the pharmaceutical and biotechnology industries, was acquired by Alcanza Clinical Research through an LBO.
Merger/Acquisition
- CMIC, provides contract research, development, and manufacturing services for pharmaceutical companies, medical device manufacturers, and biotech firms, was acquired by SGS.
- Sunrise Rx, specialty pharmacy and infusion services for patients with complex chronic conditions, was acquired by AvevoRx.
- KKT Labs, cosmetic formulation services for the development of clean beauty products, was acquired by Capsum.
Later Stage VC
- Illuminare Biotechnologies, intra-operative nerve visualization technology that reduces the risk of nerve damage, raised $4.25 million through a combination of Series B-1.
- Beren Therapeutics, cyclodextrin-based therapeutics that discover, develop, and deliver novel therapies for conditions characterized by defective cholesterol trafficking, raised $300 million of venture funding through a combination of debt and equity.
Early Stage VC
- com, dietary supplements for health-conscious consumers, raised $384,770 of venture funding.
Seed Round
- Nexara Health, a pharmaceutical platform for the healthcare and research sectors, raised $350,000 of seed funding.
#castleplacement #capitalraising #privateequity #venturecapital #investment #pharmaceuticals #drugdelivery #drugdiscovery #biotechnology
Raheem Suleman
Managing Director
Over two decades of experience in capital markets across capital raising, FX, futures, and stocks. Expertise in both business and technical aspects of trading and relationship management. Valuable insights into Asian and Middle Eastern capital markets. Broad understanding of the financial markets, and the insurance and reinsurance sectors. Extensive experience in the hospitality industry, managing multiple properties with responsibilities ranging from capital raising to daily operations. Completed the executive education program in private equity at the Wharton School. B.S. in Economics and Finance from the University of Waterloo. FINRA Series 7 and 63 licensed.
- Email: rsuleman@castleplacement.com
- (C) (646) 852-8007
Raheem Suleman
Managing Director
Please contact me if you have any questions or would like to discuss your capital raise:
Email: rsuleman@castleplacement.com
(C) (646) 852-8007
Send us a message:
Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement® does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.
